UY35462A - Formulación de un polipéptido del factor viii. - Google Patents
Formulación de un polipéptido del factor viii.Info
- Publication number
- UY35462A UY35462A UY0001035462A UY35462A UY35462A UY 35462 A UY35462 A UY 35462A UY 0001035462 A UY0001035462 A UY 0001035462A UY 35462 A UY35462 A UY 35462A UY 35462 A UY35462 A UY 35462A
- Authority
- UY
- Uruguay
- Prior art keywords
- formulation
- fviii
- polypeptide
- factor polypeptide
- fviii protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona una formulación de un polipéptido de Factor VIII, por ejemplo, FV III-Fc, y métodos para usar la misma. El polipépt ido de FVIII puede ser una proteína FVIII recombi nante, una proteína FVIII de corta duración, o un a proteína FVIII de acción prolongada. La formulación farmacéutica que comprende un polipéptido de FVIII se puede utilizar para profilaxis individual, profilaxis semanal, tratamiento episódico (a demanda), o gestión periquirúrgica de la hemofilia .
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800293P | 2013-03-15 | 2013-03-15 | |
| US201361817085P | 2013-04-29 | 2013-04-29 | |
| US201361829884P | 2013-05-31 | 2013-05-31 | |
| US201361839477P | 2013-06-26 | 2013-06-26 | |
| US201361863860P | 2013-08-08 | 2013-08-08 | |
| US201361876927P | 2013-09-12 | 2013-09-12 | |
| US201361879955P | 2013-09-19 | 2013-09-19 | |
| US201361897742P | 2013-10-30 | 2013-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35462A true UY35462A (es) | 2014-10-31 |
Family
ID=50771579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035462A UY35462A (es) | 2013-03-15 | 2014-03-14 | Formulación de un polipéptido del factor viii. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9623088B2 (es) |
| EP (3) | EP4122487A1 (es) |
| JP (5) | JP6330026B2 (es) |
| AU (3) | AU2014228506A1 (es) |
| CA (1) | CA2899737A1 (es) |
| CL (1) | CL2015002720A1 (es) |
| DK (1) | DK2968477T3 (es) |
| EA (2) | EA201890671A1 (es) |
| ES (2) | ES2776195T3 (es) |
| HK (1) | HK1220617A1 (es) |
| HU (1) | HUE047933T2 (es) |
| LT (1) | LT2968477T (es) |
| PH (2) | PH12015501801B1 (es) |
| PL (2) | PL3666283T3 (es) |
| PT (2) | PT2968477T (es) |
| RS (1) | RS60003B1 (es) |
| SG (2) | SG10201805207QA (es) |
| SI (1) | SI2968477T1 (es) |
| TW (2) | TWI690325B (es) |
| UY (1) | UY35462A (es) |
| WO (1) | WO2014144795A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101770849B1 (ko) * | 2009-12-06 | 2017-09-05 | 바이오버라티브 테라퓨틱스 인크. | 인자 ＦⅧ-Ｆｃ의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법 |
| US10588949B2 (en) | 2013-03-15 | 2020-03-17 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
| EP4122487A1 (en) * | 2013-03-15 | 2023-01-25 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759697B (zh) | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| MX2019006446A (es) | 2016-12-02 | 2019-12-11 | Bioverativ Therapeutics Inc | Métodos para inducir tolerancia inmunológica a factores de coagulación. |
| JP7039308B2 (ja) * | 2017-02-08 | 2022-03-22 | 三洋化成工業株式会社 | 細胞培養用担体 |
| SG11202000764RA (en) | 2017-08-09 | 2020-02-27 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| US10603275B2 (en) | 2017-11-07 | 2020-03-31 | Rani Therapeutics, Llc | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device |
| AU2019270184A1 (en) | 2018-05-18 | 2020-11-26 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
| KR20210042128A (ko) | 2018-08-09 | 2021-04-16 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도 |
| AU2019366942A1 (en) * | 2018-10-23 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor VIII function |
| US20220088085A1 (en) * | 2019-02-28 | 2022-03-24 | Public University Corporation Yokohama City University | Composition for treating blood coagulation and/or complement disorders |
| EP3956456A1 (en) | 2019-04-17 | 2022-02-23 | Codiak BioSciences, Inc. | Compositions of exosomes and aav |
| AU2020298233A1 (en) | 2019-06-19 | 2022-01-20 | Bioverativ Therapeutics Inc. | Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density |
| KR20230159285A (ko) * | 2022-05-10 | 2023-11-21 | 주식회사 녹십자 | 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물 |
| KR20230159284A (ko) * | 2022-05-10 | 2023-11-21 | 주식회사 녹십자 | 혈장 단백질에 대한 신규한 액상 제형물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| ATE72838T1 (de) | 1985-04-12 | 1992-03-15 | Genetics Inst | Neue prokoagulierungsproteine. |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| JP2525022B2 (ja) | 1986-01-03 | 1996-08-14 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法 |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| AU648020B2 (en) | 1989-02-21 | 1994-04-14 | Washington University | Modified forms of reproductive hormones |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| WO1992016221A1 (en) | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| SK282483B6 (sk) * | 1992-10-02 | 2002-02-05 | Genetics Institute, Inc. | Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| CZ300547B6 (cs) * | 1999-02-22 | 2009-06-10 | University Of Connecticut | Nové formulace faktoru VIII prosté albuminu |
| DE60122286T2 (de) | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| JP5424521B2 (ja) | 2001-12-21 | 2014-02-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| GB0207092D0 (en) | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| DK2298347T3 (en) | 2003-05-06 | 2016-01-11 | Biogen Hemophilia Inc | COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| EP1703899B1 (en) * | 2003-12-19 | 2011-05-04 | Novo Nordisk Health Care AG | Stabilised compositions of factor vii polypeptides |
| KR101904630B1 (ko) | 2004-11-12 | 2018-10-04 | 바이엘 헬스케어 엘엘씨 | Ｆｖｉｉｉ의 부위 지향 변형 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US8754194B2 (en) | 2006-12-22 | 2014-06-17 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| ES2362386T3 (es) | 2007-06-21 | 2011-07-04 | Technische Universität München | Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro. |
| US8239182B2 (en) | 2007-12-04 | 2012-08-07 | Spansion Llc | Data transmission system-on-chip memory model based validation |
| US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| ES2427627T3 (es) | 2009-04-06 | 2013-10-31 | Novo Nordisk A/S | Entrega dirigida de proteínas de Factor VIII a plaquetas |
| KR101770849B1 (ko) | 2009-12-06 | 2017-09-05 | 바이오버라티브 테라퓨틱스 인크. | 인자 ＦⅧ-Ｆｃ의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법 |
| TWI687226B (zh) * | 2011-07-08 | 2020-03-11 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ嵌合及雜交多肽，及其使用方法 |
| WO2013057219A1 (en) * | 2011-10-18 | 2013-04-25 | Csl Behring Gmbh | Method for improving the stability of purified factor viii after reconstitution |
| JP2015527350A (ja) * | 2012-08-13 | 2015-09-17 | ノヴォ ノルディスク アー／エス | 第ｖｉｉｉ因子の液体製剤 |
| EP3446700A1 (en) * | 2012-10-30 | 2019-02-27 | Bioverativ Therapeutics Inc. | Methods of using fviii polypeptide |
| EP4122487A1 (en) * | 2013-03-15 | 2023-01-25 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
-
2014
- 2014-03-14 EP EP22176875.7A patent/EP4122487A1/en active Pending
- 2014-03-14 HU HUE14725816A patent/HUE047933T2/hu unknown
- 2014-03-14 EA EA201890671A patent/EA201890671A1/ru unknown
- 2014-03-14 TW TW107113370A patent/TWI690325B/zh active
- 2014-03-14 EP EP14725816.4A patent/EP2968477B1/en active Active
- 2014-03-14 DK DK14725816.4T patent/DK2968477T3/da active
- 2014-03-14 ES ES14725816T patent/ES2776195T3/es active Active
- 2014-03-14 EP EP19212900.5A patent/EP3666283B1/en active Active
- 2014-03-14 US US14/213,180 patent/US9623088B2/en active Active
- 2014-03-14 JP JP2016503069A patent/JP6330026B2/ja active Active
- 2014-03-14 EA EA201591439A patent/EA030357B1/ru unknown
- 2014-03-14 PT PT147258164T patent/PT2968477T/pt unknown
- 2014-03-14 SG SG10201805207QA patent/SG10201805207QA/en unknown
- 2014-03-14 ES ES19212900T patent/ES2926798T3/es active Active
- 2014-03-14 SI SI201431514T patent/SI2968477T1/sl unknown
- 2014-03-14 SG SG11201505924TA patent/SG11201505924TA/en unknown
- 2014-03-14 CA CA2899737A patent/CA2899737A1/en active Pending
- 2014-03-14 PL PL19212900.5T patent/PL3666283T3/pl unknown
- 2014-03-14 TW TW103109616A patent/TWI629993B/zh active
- 2014-03-14 WO PCT/US2014/029354 patent/WO2014144795A1/en active Application Filing
- 2014-03-14 LT LTEP14725816.4T patent/LT2968477T/lt unknown
- 2014-03-14 AU AU2014228506A patent/AU2014228506A1/en not_active Abandoned
- 2014-03-14 RS RS20200243A patent/RS60003B1/sr unknown
- 2014-03-14 UY UY0001035462A patent/UY35462A/es not_active Application Discontinuation
- 2014-03-14 PT PT192129005T patent/PT3666283T/pt unknown
- 2014-03-14 PL PL14725816T patent/PL2968477T3/pl unknown
-
2015
- 2015-08-14 PH PH12015501801A patent/PH12015501801B1/en unknown
- 2015-09-15 CL CL2015002720A patent/CL2015002720A1/es unknown
-
2016
- 2016-07-20 HK HK16108672.0A patent/HK1220617A1/zh unknown
-
2017
- 2017-03-09 US US15/455,043 patent/US10786554B2/en active Active
-
2018
- 2018-04-23 JP JP2018082321A patent/JP2018123161A/ja not_active Ceased
-
2019
- 2019-04-16 AU AU2019202656A patent/AU2019202656B2/en active Active
- 2019-10-30 PH PH12019502452A patent/PH12019502452A1/en unknown
-
2020
- 2020-08-14 US US16/993,979 patent/US20210069300A1/en active Pending
- 2020-08-19 JP JP2020138637A patent/JP6934994B2/ja active Active
-
2021
- 2021-08-24 JP JP2021136162A patent/JP7240457B2/ja active Active
- 2021-11-29 AU AU2021277601A patent/AU2021277601A1/en active Pending
-
2023
- 2023-03-03 JP JP2023032892A patent/JP2023060146A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35462A (es) | Formulación de un polipéptido del factor viii. | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| CL2022003763A1 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
| CY1121560T1 (el) | Ανοσογονικη συνθεση | |
| BR112017005381A2 (pt) | composições que compreendem células recombinantes de bacillus e um inseticida. | |
| GT201700150A (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2017002729A1 (es) | Proteína de unión a rgma y su uso | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112017005504A2 (pt) | composições que compreendem células recombinantes de bacillus e um inseticida. | |
| AR102203A1 (es) | Composiciones para el cuidado oral que comprenden zinc, arginina y serina | |
| SV2017005515A (es) | Formulaciones de polvo nasal para el tratamiento de la hipoglicemia | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| UY35463A (es) | Formulaciones de polipéptido fc-factor ix. | |
| CL2017003144A1 (es) | Péptidos lipidados resistentes a proteasas | |
| MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
| UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
| SG10201809099PA (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| MX2019008529A (es) | Peptidos mimeticos de apolipoproteina c-ii (apoc-ii). | |
| AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211206 |